Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Abstract Introduction Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. Methods This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalido...

Full description

Saved in:
Bibliographic Details
Main Authors: Barry Paul, Jiri Minarik, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Usmani, Mei Dong, Lin Gu, Carmen Leung, Parul Doshi, Christine Chen, Ludek Pour
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Subjects:
carfilzomib
daratumumab
dexamethasone
magrolimab
pomalidomide
relapsed/refractory multiple myeloma
Online Access:https://doi.org/10.1002/jha2.70072
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jha2.70072

Similar Items